The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis

Respiratory Medicine

Volumn 107, Issue 2, 2013, Pages 292-297

  Jo, Kyung Wook ^a   Ji, Wonjun ^a   Hong, Yoonki ^a   Lee, Sang Do ^a   Kim, Woo Sung ^a   Kim, Dong Soon ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Efficacy; Multidrug resistant tuberculosis; Rifabutin

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; STREPTOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; CASE-CONTROL STUDIES; DRUG EVALUATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RIFABUTIN; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872109041     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.10.021     Document Type: Article

References (33)

1. A. Wright, M. Zignol, and A. Van Deun Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculous drug resistance surveillance Lancet 373 2009 1861 1873
2. World Health Organization Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control Wkly Epidemiol Rec 81 2006 430 432
3. G.H. Bai, Y.K. Park, and Y.W. Choi Trend of anti-tuberculosis drug resistance in Korea, 1994-2004 Int J Tuberc Lung Dis 11 2007 571 576
4. S.Y. Kim, H.J. Kim, and C.K. Kim The recent status of multidrug- and extensively drug-resistant tuberculosis in Korea Tuberc Respir Dis 68 2010 146 154
5. D.H. Kim, H.J. Kim, and S.K. Park Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 2010 113 119
6. World Health Organization Treatment of tuberculosis guidelines 4th ed. 2009
7. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Treatment of tuberculosis Am J Respir Crit Care Med 167 2003 603 662
8. G. Davies, S. Cerri, and L. Richeldi Rifabutin for treating pulmonary tuberculosis Cochrane Database Syst Rev 4 2007 CD005159
9. M.M. McGregor, P. Olliaro, and L. Wolmarans Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis Am J Respir Crit Care Med 154 1996 1462 1467
10. C. Grassi, and V. Peona Use of rifabutin in the treatment of pulmonary tuberculosis Clin Infect Dis 22 1996 S50 S54
11. C.N. Lee, T.P. Lin, M.F. Chang, M.V. Jimenez, L. Dolfi, and P. Olliaro Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan J Chemother 8 1996 137 143
12. A. Telenti Genetics of drug resistance in tuberculosis M.D. Iseman, G.A. Huitt, Clinics in chest medicine 1997 WB Saunders Philadelphia 55 64
13. M. Uzun, Z. Erturan, and O. Anǧ Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains Int J Tuberc Lung Dis 6 2002 164 165
14. W.J. Lew, Y.K. Park, H.J. Kim, C. Chang, G.H. Bai, and S.K. Kim The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations Tuberc Respir Dis 59 2005 257 265
15. B.J. Kim, S.H. Oh, E.J. Cho, and S.K. Park Cross-resistance between rifampicin and rifabutin and its relationship with rpoB gene mutations in clinically isolated MDR-TB strains Tuberc Respir Dis 60 2006 171 179
16. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis Geneva, Switzerland 2008
17. National Tuberculosis Association Diagnostic standards and classification of tuberculosis 1961 The National Tuberculosis Association New York
18. Treatment of tuberculosis MMWR Recomm Rep 52 RR-11 2003 1 77
19. J.M. Dickinson, and D.A. Mitchinson In vitro activity of newrifamycins against rifampicin-resistant M. tuberculosisand MAIS-complex mycobacteria Tubercle 68 1987 177 182
20. J.M. Musser Antimicrobial agent resistance in mycobacteria: molecular genetic insights Clin Microbiol Rev 8 1995 496 514
21. L.J. Gonzalez-Montaner, S. Natal, P. Yongchaiyud, and P. Olliaro Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group Tuber Lung Dis 75 1994 341 347
22. W.W. Yew, C.H. Chau, and K.H. Wen Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis Int J Tuberc Lung Dis 12 2008 345 346
23. D.H. Kim, H.J. Kim, and S.K. Park Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis Am J Respir Crit Care Med 178 2008 1075 1082
24. S.S. Hwang, H.R. Kim, and H.J. Kim Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Eur Respir J 33 2009 581 585
25. A. Telenti, P. Imboden, and F. Marchesi Detection of rifampin-resistance mutations in Mycobacterium tuberculosis Lancet 341 1993 647 650
26. C. Cavusoglu, Y. Karaca-Derici, and A. Bilgic In-vitroactivity of rifabutinagainstrifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations Clin Microbiol Infect 10 2004 662 665
27. G. Senol, A. Erbaycu, and A. Ozsöz Incidence of crossresistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey J Chemother 17 2005 380 384
28. K. Chikamatsu, K. Mizuno, H. Yamada, and S. Mitarai Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains Kekkaku 84 2009 631 633
29. B. Yang, H. Koga, and H. Ohno Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis J Antimicrob Chemother 42 1998 621 628
30. D.L. Williams, L. Spring, and L. Collins Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis Antimicrobial Agents Chemother 42 1998 1853 1857
31. E.A. Campbell, O. Pavlova, and N. Zenkin Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase EMBO J 24 2005 674 682
32. B.Y. Choi Perspectives of polices on HIV/AIDS and tuberculosis control in Korea Korean J Epidemiol 28 2006 75 84
33. C.H. Lee, J.Y. Hwang, and J.Y. Bae HIV/tuberculosis co-infection in Korea [abstract] Tuberc Respir Dis 61 2007 62